Researchers conducted a trial in five ICUs at an academic center, assigning 15,802 adults to receive either saline or balanced crystalloids. The primary outcome was a major adverse kidney event within 30 days, a composite of death from any cause, new renal-replacement therapy or persistent renal dysfunction.
Of the 7,942 patients in the balanced crystalloids group, 14.3 percent had a major adverse kidney event, whereas 15.4 percent of 1,211 in the saline group experienced the same event.
Researchers also found in-hospital mortality at 30 days was 10.3 percent in the balanced-crystalloids group and 11.1 percent in the saline group.
Additionally, the incidence of new renal-replacement therapy was 2.5 percent in the balanced-crystalloids group and 2.9 percent in the saline group. The incidence of persistent renal dysfunction was 6.4 percent in the former group and 6.6 in the latter.
More articles on healthcare quality:
How Rush hospital is working to tackle Chicago’s ‘death gap’
Can FMT clear CRE, VRE from the digestive tract?
Expanded care model improves quality of life for chronic heart failure patients
